Esther Bommer

518 total citations
5 papers, 66 citations indexed

About

Esther Bommer is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Esther Bommer has authored 5 papers receiving a total of 66 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Immunology. Recurrent topics in Esther Bommer's work include CAR-T cell therapy research (5 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Esther Bommer is often cited by papers focused on CAR-T cell therapy research (5 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Esther Bommer collaborates with scholars based in Switzerland. Esther Bommer's co-authors include Christian Klein, Marina Bacac, Pablo Umaña, Johannes Sam, Sara Colombetti, Linda Fahrni, Maria Karagianni, Valeria Nicolini, Tanja Fauti and Sylvia Herter and has published in prestigious journals such as Blood, Cancer Research and Clinical Cancer Research.

In The Last Decade

Esther Bommer

5 papers receiving 65 citations

Peers

Esther Bommer

ONCOL

RNMI

IMMUN

MB

PFM

Erica Hong United States

Anushka De Costa United States

Drew Dudgeon United States

Kristin Vazzana United States

May Ji United States

Maria Dasovich

Guenther Koehne United States

Peter Bruenker Switzerland

Andrey Meshcheryakov Russia

Aleksandar Murgaski Belgium

Erica Hong United States

Esther Bommer

38 ×0.7

ONCOL

30 ×0.8

RNMI

7 ×0.2

IMMUN

13 ×1.0

MB

9 ×1.0

PFM

Citations per year, relative to Esther Bommer Esther Bommer (= 1×) peers Erica Hong

Countries citing papers authored by Esther Bommer

Since Specialization

Citations

This map shows the geographic impact of Esther Bommer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esther Bommer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esther Bommer more than expected).

Fields of papers citing papers by Esther Bommer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Esther Bommer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esther Bommer. The network helps show where Esther Bommer may publish in the future.

Co-authorship network of co-authors of Esther Bommer

This figure shows the co-authorship network connecting the top 25 collaborators of Esther Bommer. A scholar is included among the top collaborators of Esther Bommer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Esther Bommer. Esther Bommer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Sam, Johannes, Sara Colombetti, Tanja Fauti, et al.. (2020). Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity. Frontiers in Oncology. 10. 575737–575737. 38 indexed citations

2.

Herter, Sylvia, Johannes Sam, Claudia Ferrara, et al.. (2020). RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies. Blood. 136(Supplement 1). 40–40. 8 indexed citations

3.

Nicolini, Valeria, Inja Waldhauer, Anne Freimoser–Grundschober, et al.. (2020). Abstract LB-389: Combination of TYRP1-TCB, a novel T cell bispecific antibody for the treatment of melanoma, with immunomodulatory agents. Cancer Research. 80(16_Supplement). LB–389. 6 indexed citations

4.

Klein, Christian, Laura Codarri Deak, Valeria Nicolini, et al.. (2019). Abstract 1552: A novel PD1-IL2v immunocytokine for preferential cis-activation of IL-2R signaling on PD-1 expressing T cell subsets strongly potentiates anti-tumor T cell activity of PD-1 checkpoint inhibition and IL-2R-beta-gamma agonism. Cancer Research. 79(13_Supplement). 1552–1552. 6 indexed citations

5.

Gonzalez‐Nicolini, Valeria, Sylvia Herter, Sabine M. Lang, et al.. (2015). Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy. Clinical Cancer Research. 22(10). 2453–2461. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact